The presence of the c-KIT D816V mutation in our case strengthens an alternative hypothesis where similar to the enrichment of TP53 mutations in other therapy-related myeloid malignancies, radiation therapy might select for a clonal population of mast cells with a potential survival advantage due to the presence of the c-KIT mutation [17]. This evidence concerns the gene TP53 and myeloid neoplasm.